Handelsbanken Fonder AB Makes New $841,000 Investment in Ocular Therapeutix, Inc. $OCUL

Handelsbanken Fonder AB acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, Holdings Channel.com reports. The fund acquired 69,300 shares of the biopharmaceutical company’s stock, valued at approximately $841,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Ocular Therapeutix by 26.3% during the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after purchasing an additional 2,411,953 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Ocular Therapeutix by 38.5% in the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after acquiring an additional 2,850,000 shares in the last quarter. TCG Crossover Management LLC raised its holdings in shares of Ocular Therapeutix by 15.0% in the third quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock valued at $71,510,000 after acquiring an additional 798,084 shares in the last quarter. Millennium Management LLC lifted its stake in Ocular Therapeutix by 3,136.1% in the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after acquiring an additional 3,736,560 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its holdings in Ocular Therapeutix by 2.3% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 3,497,307 shares of the biopharmaceutical company’s stock worth $40,884,000 after acquiring an additional 76,967 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OCUL has been the topic of a number of research reports. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Monday, April 13th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Chardan Capital restated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Finally, William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.78.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $8.54 on Thursday. The company has a market capitalization of $1.87 billion, a PE ratio of -5.85 and a beta of 0.93. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The company has a 50-day simple moving average of $8.78 and a two-hundred day simple moving average of $10.24. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.